Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements

被引：0

作者：

Kim, Kyuhwan ^{[1
,2
]}

Kim, Kyu Yean ^{[3
]}

Kang, Hye Seon ^{[4
]}

Shin, Ah Young ^{[5
]}

Kim, Sung Kyoung ^{[6
]}

Park, Chan Kwon ^{[7
]}

Lee, Sang Haak ^{[8
]}

Kim, Seung Joon ^{[8
,9
]}

Lim, Jeong Uk ^{[7
]}

Yeo, Chang Dong ^{[8
]}

机构：

[1] Catholic Univ Korea, Seoul St Marys Hosp, Div Pulm Allergy & Crit Care Med, Dept Internal Med,Coll Med, Seoul, South Korea

[2] Armed Forces Goyang Hosp, Dept Internal Med, Goyang, South Korea

[3] Catholic Univ Korea, Coll Med, Dept Internal Med, Dept Internal Med,Div Pulm Crit Care Med, Uijeongbu Si 11765, South Korea

[4] Catholic Univ Korea, Dept Internal Med, Div Pulm & Crit Care Med, Bucheon St Marys Hosp,Coll Med, Bucheon Si, South Korea

[5] Catholic Univ Korea, Incheon St Marys Hosp, Div Pulm & Crit Care Med, Dept Internal Med,Coll Med, Incheon, South Korea

[6] Catholic Univ Korea, St Vincents Hosp, Div Pulm & Crit Care Med, Dept Internal Med,Coll Med, Suwon, South Korea

[7] Catholic Univ Korea, Yeouido St Marys Hosp, Coll Med, Dept Internal Med,Div Pulm & Crit Care Med, 10,63 Ro, Seoul 07345, South Korea

[8] Catholic Univ Korea, Eunpyeong St Marys Hosp, Coll Med, Dept Internal Med,Div Pulm Crit Care & Sleep Med, 1021 Tongil Ro, Seoul 03312, South Korea

[9] Catholic Univ Korea, Postech Catholic Biomed Engn Inst, Coll Med, Songeui Multiplex Hall, Seoul, South Korea

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2025年 / 17卷

关键词：

alectinib; anaplastic lymphoma kinase; brigatinib; carcinoma; non-small-cell lung; CELL LUNG-CANCER; CRIZOTINIB; CHEMOTHERAPY; INHIBITORS; SMOKING; ASSOCIATION; MUTATIONS; SURVIVAL; EFFICACY;

D O I：

10.1177/17588359251316200

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background and objectives: This study aimed to compare the efficacy of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) alectinib and brigatinib in the treatment of advanced non-small-cell lung cancer (NSCLC) with ALK rearrangements based on real-world data. Design and methods: We conducted a multicenter retrospective study using the Clinical Data Warehouse from seven university hospitals affiliated with the Catholic Medical Center. Patients diagnosed with ALK-positive advanced NSCLC and treated with alectinib or brigatinib were included. Key outcomes such as time to discontinuation (TTD), duration of response (DOR), overall survival (OS), and objective response rate (ORR) were analyzed. Results: A total of 143 patients were included (107 treated with alectinib, 36 with brigatinib). Alectinib was more frequently used as a first-line treatment (71% vs 44.4% for brigatinib, p = 0.008). Prior crizotinib treatment was more frequent in the brigatinib group (52.8% vs 22.4% for alectinib, p < 0.001). The best ORR was similar between the groups (84.1% for alectinib vs 83.3% for brigatinib, p = 0.518). The median TTD was 57.8 months (95% confidence interval (CI): 29.0-86.7) for alectinib and 39.6 months (95% CI: 21.7-57.4) for brigatinib (p = 0.462). No significant differences were observed in intracranial TTD, intracranial DOR, or OS between the groups. Prior crizotinib treatment significantly shortened TTD for second-generation TKIs (p = 0.025), but the overall TKI treatment duration did not show a significant difference between patients who received frontline second-generation ALK TKIs and those who received second-generation ALK TKIs sequentially after crizotinib. Conclusion: Alectinib and brigatinib demonstrated comparable efficacy in ALK-positive advanced NSCLC. Undergoing crizotinib followed by a second-generation TKI was not significantly different from initiating a second-generation TKI without prior crizotinib in terms of outcomes.

引用

页数：15

共 30 条

[1] The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2) [J].

Aisner, Dara L. ;

Sholl, Lynette M. ;

Berry, Lynne D. ;

Rossi, Michael R. ;

Chen, Heidi ;

Fujimoto, Junya ;

Moreira, Andre L. ;

Ramalingam, Suresh S. ;

Villaruz, Liza C. ;

Otterson, Gregory A. ;

Haura, Eric ;

Politi, Katerina ;

Glisson, Bonnie ;

Cetnar, Jeremy ;

Garon, Edward B. ;

Schiller, Joan ;

Waqar, Saiama N. ;

Sequist, Lecia V. ;

Brahmer, Julie ;

Shyr, Yu ;

Kugler, Kelly ;

Wistuba, Ignacio I. ;

Johnson, Bruce E. ;

Minna, John D. ;

Kris, Mark G. ;

Bunn, Paul A. ;

Kwiatkowski, David J. .

CLINICAL CANCER RESEARCH, 2018, 24 (05) :1038-1047

[2] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer [J].

Camidge, D. R. ;

Kim, H. R. ;

Ahn, M. -J. ;

Yang, J. C. -H. ;

Han, J. -Y. ;

Lee, J. -S. ;

Hochmair, M. J. ;

Li, J. Y. -C. ;

Chang, G. -C. ;

Lee, K. H. ;

Gridelli, C. ;

Delmonte, A. ;

Garcia Campelo, R. ;

Kim, D. -W. ;

Bearz, A. ;

Griesinger, F. ;

Morabito, A. ;

Felip, E. ;

Califano, R. ;

Ghosh, S. ;

Spira, A. ;

Gettinger, S. N. ;

Tiseo, M. ;

Gupta, N. ;

Haney, J. ;

Kerstein, D. ;

Popat, S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2027-2039

[3] Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial [J].

Camidge, D. Ross ;

Kim, Hye Ryun ;

Ahn, Myung-Ju ;

Yang, James C. H. ;

Han, Ji-Youn ;

Hochmair, Maximilian J. ;

Lee, Ki Hyeong ;

Delmonte, Angelo ;

Campelo, Maria Rosario Garcia ;

Kim, Dong-Wan ;

Griesinger, Frank ;

Felip, Enriqueta ;

Califano, Raffaele ;

Spira, Alexander I. ;

Gettinger, Scott N. ;

Tiseo, Marcello ;

Lin, Huamao M. ;

Liu, Yuyin ;

Vranceanu, Florin ;

Niu, Huifeng ;

Zhang, Pingkuan ;

Popat, Sanjay .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) :2091-2108

[4] Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression [J].

Chen, Rui-Lian ;

Zhao, Jun ;

Zhang, Xu-Chao ;

Lou, Na-Na ;

Chen, Hua-Jun ;

Yang, Xue ;

Su, Jian ;

Xie, Zhi ;

Zhou, Qing ;

Tu, Hai-Yan ;

Zhong, Wen-Zhao ;

Yan, Hong-Hong ;

Guo, Wei-Bang ;

Wu, Yi-Long ;

Yang, Jin-Ji .

BMC CANCER, 2018, 18

[5] The Central Nervous System as a Sanctuary Site in ALK-Positive Non-Small-Cell Lung Cancer [J].

Gainor, Justin F. ;

Ou, Sai-Hong Ignatius ;

Logan, Jennifer ;

Borges, Lawrence F. ;

Shaw, Alice T. .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (12) :1570-1573

[6] ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer [J].

Gainor, Justin F. ;

Varghese, Anna M. ;

Ou, Sai-Hong Ignatius ;

Kabraji, Sheheryar ;

Awad, Mark M. ;

Katayama, Ryohei ;

Pawlak, Amanda ;

Mino-Kenudson, Mari ;

Yeap, Beow Y. ;

Riely, Gregory J. ;

Iafrate, A. John ;

Arcila, Maria E. ;

Ladanyi, Marc ;

Engelman, Jeffrey A. ;

Dias-Santagata, Dora ;

Shaw, Alice T. .

CLINICAL CANCER RESEARCH, 2013, 19 (15) :4273-4281

[7] Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALKþ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials [J].

Gettinger, Scott N. ;

Huber, Rudolf M. ;

Kim, Dong-Wan ;

Bazhenova, Lyudmila ;

Hansen, Karin Holmskov ;

Tiseo, Marcello ;

Langer, Corey J. ;

Rodriguez, Luis G. Paz-Ares ;

West, Howard L. ;

Reckamp, Karen L. ;

Weiss, Glen J. ;

Smit, Egbert F. ;

Hochmair, Maximilian J. ;

Kim, Sang-We ;

Ahn, Myung-Ju ;

Kim, Edward S. ;

Groen, Harry J. M. ;

Pye, Joanna ;

Liu, Yuyin ;

Zhang, Pingkuan ;

Vranceanu, Florin ;

Camidge, Ross .

JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (09)

[8] Comorbidity and Survival in Lung Cancer Patients [J].

Islam, K. M. Monirul ;

Jiang, Xiaqing ;

Anggondowati, Trisari ;

Lin, Ge ;

Ganti, Apar Kishor .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (07) :1079-1085

[9]

Jiang J, 2022, BMJ OPEN, V12, DOI 10.1136/bmjopen-2022-060782

[10] EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer [J].

Koivunen, Jussi P. ;

Mermel, Craig ;

Zejnullahu, Kreshnik ;

Murphy, Carly ;

Lifshits, Eugene ;

Holmes, Alison J. ;

Choi, Hwan Geun ;

Kim, Jhingook ;

Chiang, Derek ;

Thomas, Roman ;

Lee, Jinseon ;

Richards, William G. ;

Sugarbaker, David J. ;

Ducko, Christopher ;

Lindeman, Neal ;

Marcoux, J. Paul ;

Engelman, Jeffrey A. ;

Gray, Nathanael S. ;

Lee, Charles ;

Meyerson, Matthew ;

Janne, Pasi A. .

CLINICAL CANCER RESEARCH, 2008, 14 (13) :4275-4283

← 1 2 3 →